All cell-based immunotherapies inspire hope for a less cancer-plagued future, especially the ones that engineer T cells to detect and destroy cancer cells. Of all the engineered T cells that have been developed, one stands out—at least when it comes to regulatory approvals for clinical use. This is the chimeric antigen receptor (CAR) T cell. […]
The post Crafting a More Efficient CAR T-Cell Industry appeared first on GEN - Genetic Engineering and Biotechnology News.
Original Article: Crafting a More Efficient CAR T-Cell Industry